Clinical Trials Logo

PHACE Syndrome clinical trials

View clinical trials related to PHACE Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT05133245 Enrolling by invitation - PHACE Syndrome Clinical Trials

PHACE - Prospective Genetic Investigation

PHACE
Start date: November 1, 2021
Phase:
Study type: Observational

Investigation for potential PHACE syndrome gene.

NCT ID: NCT03440697 Recruiting - Clinical trials for Aortic Valve Disease

Pathogenetic Basis of Aortopathy and Aortic Valve Disease

TAA
Start date: December 10, 2015
Phase:
Study type: Observational

The main purpose of this study is to define the complex genetic and pathogenic basis of thoracic aortic aneurysm (TAA) and other forms of aortopathy and/or aortic valve disease by identifying novel disease-causing genes and by identifying important genetic modifiers for aortic and aortic valve disease severity.

NCT ID: NCT01018082 Completed - PHACE Syndrome Clinical Trials

Longitudinal Study of Neurologic, Cognitive, and Radiologic Outcomes of PHACE Syndrome

PHACE
Start date: September 2009
Phase: N/A
Study type: Observational

The overall goal of this 2-year pilot project is to utilize interdisciplinary strategies to determine the prevalence and type of neurodevelopmental impairment in PHACE syndrome, a rare vascular syndrome, and to rapidly translate discovery into clinical care guidelines that will identify at risk infants so early intervention can be initiated. Infantile hemangioma is the most common benign tumor of infancy, with an incidence estimated between 4-5%. A subgroup of patients with infantile hemangiomas exhibits additional associated structural anomalies of the brain, cerebral vasculature, eyes, aorta, heart, and chest wall in the rare neurocutaneous disorder called PHACE syndrome (OMIM 606519). PHACE refers to Posterior fossa anomalies, Hemangioma, Arterial lesions, Cardiac abnormalities/aortic coarctation, and abnormalities of the Eye. Affected children have multi-organ involvement, and an increasing number of cerebral, cerebellar, and cerebrovascular anomalies are being described; however, the significance of these neuroradiologic findings is not known. As the investigators' neonates with hemangiomas have grown into young children, neurodevelopmental impairment has become more evident, even among patients without MRI evidence of stroke or structural brain anomalies. Some infants develop progressive cerebral arterial disease leading to a moyamoya-like vasculopathy and ischemic stroke. An interdisciplinary research project studying brain and cerebral vascular imaging in concert with neurological, psychological, behavioral, neurodevelopmental, and quality of life outcome measures has never been conducted. Diagnostic and management guidelines are also lacking. The investigators' long-term goal is to develop medical and/or surgical therapeutic interventions that improve the overall health of children with PHACE syndrome. This novel project constitutes the first study of the most devastating feature of PHACE syndrome: the neurodevelopmental sequelae.

NCT ID: NCT01016756 Completed - PHACE Syndrome Clinical Trials

Genetic Analysis of PHACE Syndrome (Hemangioma With Other Congenital Anomalies)

PHACE
Start date: February 2007
Phase:
Study type: Observational

1. PHACE syndrome(OMIM database number 606519) is the association of a vascular birthmark (hemangioma) on the face along with one or more of the following conditions: congenital heart defects, congenital anomalies of the cerebral arteries,brain, eyes, or sternum. 2. A research study is currently being conducted at the Medical College of Wisconsin (MCW) to investigate if there is an inherited cause of PHACE syndrome. 3. We are hoping that this study will lead to a better understanding of how and why children develop PHACE syndrome.